AGALIMMUNE LTD.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.agalimmune.com
Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour
Phase 1
Completed
- Conditions
- Superficial, Palpable, Unresectable/Metastatic Solid Tumour
- Interventions
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Agalimmune Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT03593226
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸AHS Hospital Corp., Morristown, New Jersey, United States
🇺🇸Providence Cancer Institute Franz Clinic, Portland, Oregon, United States
© Copyright 2025. All Rights Reserved by MedPath